{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:30:47Z","timestamp":1783099847363,"version":"3.54.6"},"reference-count":26,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.clml.2015.02.023","type":"journal-article","created":{"date-parts":[[2015,3,4]],"date-time":"2015-03-04T23:56:13Z","timestamp":1425513373000},"page":"404-408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Safety and Efficacy of Single-Agent Bendamustine After Failure of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin's Lymphoma: Experience With 27 Patients"],"prefix":"10.1016","volume":"15","author":[{"given":"Pier Luigi","family":"Zinzani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Vitolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Viviani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Cascavilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hohaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Merli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Argnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Broccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.02.023_bib1","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.6004\/jnccn.2011.0087","article-title":"The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma","volume":"9","author":"Holmberg","year":"2011","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2015.02.023_bib2","first-page":"CD007941","article-title":"Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma","volume":"8","author":"Bauer","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clml.2015.02.023_bib3","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2015.02.023_bib4","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haematopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2015.02.023_bib5","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.1999.17.1.222","article-title":"Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study","volume":"17","author":"Andre","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.023_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2008.06998.x","article-title":"Managing relapsed and refractory Hodgkin lymphoma","volume":"141","author":"Brice","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.02.023_bib7","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1182\/blood-2010-09-288373","article-title":"How I treat relapsed and refractory Hodgkin lymphoma","volume":"117","author":"Kuruvilla","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.023_bib8","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.023_bib9","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/blood-2012-05-430918","article-title":"Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience","volume":"120","author":"Rothe","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.023_bib10","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3324\/haematol.2012.069393","article-title":"Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK Centre","volume":"98","author":"Gibb","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.02.023_bib11","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3324\/haematol.2012.083048","article-title":"Brentuximab vedotin in relapsed\/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily practice outside clinical trials","volume":"98","author":"Zinzani","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.02.023_bib12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00277-014-2215-9","article-title":"Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey","volume":"94","author":"Salihoglu","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2015.02.023_bib13","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3109\/10428194.2013.819575","article-title":"18-Fluorodeoxyglucose positron emission tomography\/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma","volume":"55","author":"Kahraman","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2015.02.023_bib14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00277-012-1525-z","article-title":"Bendamustine salvage for the treatment of relapsed Hodgkin's lymphoma after allogeneic bone marrow transplantation","volume":"92","author":"Mian","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2015.02.023_bib15","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hon.1004","article-title":"Successful administration of rituximab-bendamustine regimen in the relapse of Hodgkin lymphoma after autologous hemopoietic stem cell transplantation","volume":"30","author":"Magyari","year":"2012","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2015.02.023_bib16","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","article-title":"Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma","volume":"31","author":"Moskowitz","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.023_bib17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/bjh.12120","article-title":"Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma","volume":"160","author":"Corazzelli","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.02.023_bib18","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.3109\/10428194.2013.776165","article-title":"Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients","volume":"54","author":"Ghesqui\u00e8res","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2015.02.023_bib19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/bjh.12821","article-title":"Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi","volume":"166","author":"Anastasia","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.02.023_bib20","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.023_bib21","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2967\/jnumed.112.110890","article-title":"International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers","volume":"54","author":"Biggi","year":"2013","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.clml.2015.02.023_bib22","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.023_bib23","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.clml.2015.02.023_bib24","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1053\/j.seminhematol.2011.03.003","article-title":"Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity","volume":"48","author":"Leoni","year":"2011","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2015.02.023_bib25","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/bjh.12548","article-title":"Bendamustine efficacy in Hodgkin lymphoma patients relapsed\/refractory to brentuximab vedotin","volume":"163","author":"Zinzani","year":"2013","journal-title":"Br J Haematol"},{"issue":"suppl","key":"10.1016\/j.clml.2015.02.023_bib26","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/j.bbmt.2013.12.257","article-title":"A\u00a0phase 1\/2 single-arm, open-label study to evaluate the safety and efficacy of brentuximab vedotin in combination with bendamustine for patients with Hodgkin lymphoma in the first\u00a0salvage setting: interim results","volume":"20","author":"LaCasce","year":"2014","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015000671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015000671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T13:26:09Z","timestamp":1537795569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015000671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S2152265015000671"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.02.023","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Single-Agent Bendamustine After Failure of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin's Lymphoma: Experience With 27 Patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.02.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}